Powered by Jitbit AspNetForum free trial version.


Home » Announcements » Pharmaceutical Intermediate Octreotide 79517-01-4 Messages in this topic - RSS
9/27/2019 12:29:19 PM
Posts 347
Pharmaceutical Intermediate Octreotide 79517-01-4 for Research with GMP

English name: Octreotide powder
anothername:L-cysteinamide,D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl) propyl)-cyclic (2->7)-disulfide, (R-(R*,R*))
Synonyms:11: PN:US20030229017 PAGE: 13 claimed protein;14: PN: DE10147056 PAGE: 40 claimedprotein;17: PN: US6268342 SEQID: 18 claimed protein;1: PN: EP1118336 SEQID: 1claimed protein;1: PN: WO2005007122 TABLE: 22 claimed protein;25: PN:WO2007081792 SEQID: 40 claimed protein;2: PN: EP1358890 TABLE: A claimedprotein;Longastatin;L-Cysteinamide,D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2
Specification: 98%
CAS NO.: 83150-76-9
Molecular weight:1019.2393
Formula Weight: 1019.24
Molecular formula: C49H66N10O10S2
boilling point:1447.228°C at 760 mmHg
Specification of Octreotide :
1) Purity (HPLC) 98.0%min.
2) Molecular Formula: C49H66N10O10S2
3) Molecular Weight 1019.28
4) Appearance White powder
5) Single Impurity (HPLC) 1.0%max
6) Amino Acid Composition ±10% of theoretical
7) Peptide Content (N%) >80.0%
8) Water Content(Karl Fischer) <7.0%
9) Acetate Content(HPIC) <12.0%
10) Specific Rotation (20/D) -45.0~-50.0°(c=0.5 95%HAc)
11) MS (ESI) Consistent
12) Mass Balance 95.0~105.0%

Approved uses of Octreotide :
The Food and Drug Administration (FDA) has approved the usage of a salt form of this peptide, octreotide acetate, as an injectable depot formulation for the treatment of acromegaly, gigantism, thyrotropinoma, diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in patients with vasoactive intestinal peptide-secreting tumors (VIPomas).
pages: 1

Home » Announcements » Pharmaceutical Intermediate Octreotide 79517-01-4